According to the latest market report published by Credence Research, Inc. “Asthma and COPD Drugs Market By Drug Type (Anti-Inflammatory Drugs, Bronchodilator Monotherapy, Combination Drugs, Pipeline Analysis) - Growth, Future Prospects And Competitive Analysis 2017 – 2025,” the global asthma and COPD drugs market was valued at US$ 39,021.2 Mn in 2016, and is expected to reach US$ 56,507.7 Mn by 2025, expanding at a CAGR of 4.2% from 2017 to 2025.
Market Insights
Globally, asthma and COPD is one the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. Thus, disease represent a lucrative market for pharmaceutical companies. COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risk such as smoking, pollution is not addressed. Gradually over the period of time the treatment of asthma and COPD shows improvement, with novel drugs and treatment strategies, along with usage of non-pharmacologic treatment. It has being observed there is being surge in prevalence of asthma and COPD in developed and developing countries. In developed countries, there is being rise in prevalence of asthma due to lifestyle changes in terms of food habit, low level of exercise, etc., while in developing countries the prevalence is due to pollution and smoking.
Browse the full report at https://www.credenceresearch.com/report/asthma-and-copd-drugs-market
The global asthma and COPD drugs market is segmented by drug type into anti-inflammatory drugs, bronchodilator monotherapy and combination drugs. Anti-inflammatory drugs includes corticosteroids, anti-leukotrienes and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonist (SABAs) and long-acting beta2-agonist (LABAs) and anticholinergic drugs. Amongst all, combination therapy of long-acting beta2 agonist (LABA)/ inhaled corticosteroid (ICS) dominates the market. The combination therapy that include Symbicort (AstraZeneca), Advair (GlaxoSmithKline) is most preferred treatment against asthma/ COPD, due to better efficacy and less side effects.
As of the current market scenario, North America together dominate the global asthma and COPD drugs market followed by the European market. Rising prevalence of asthma and COPD due to pollution, change in lifestyle, entry of generics and novel therapies in the market. Asia Pacific is anticipated to be the fastest growing market for the forecast period. Emerging economies such India, China due to industrialization, demographic changes, urbanization there is been rise in pollution thus increase in prevalence of asthma and COPD population.
Market Competition Assessment:
Key players in the global asthma and COPD drugs market are Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer Inc. and others.
Key Market Movements:
- There is a rise in the prevalence of asthma and COPD in both developed and developing countries. In developed countries, the rise in prevalence is mainly due to lifestyle change such as smoking, while in developing countries rise is observed due to presence of most polluted cities in the world and inclusion of smoking in lifestyle
- Introduction of novel technology, strong pipeline, and personalization of medicine is also expected to drive the growth of market.
- With economic development in emerging economies, healthcare awareness, and high disposable income are some of the factors driving the developing countries
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58486
Table of Content
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Asthma and COPD Market Portraiture
2.2 Global Asthma and COPD Market Share, by Drug type, 2016 Vs 2025 (Value %)
2.3 Global Asthma and COPD Market, by Geography, 2016 (Value %)
2.1 Global Asthma and COPD Market Portraiture
2.2 Global Asthma and COPD Market Share, by Drug type, 2016 Vs 2025 (Value %)
2.3 Global Asthma and COPD Market, by Geography, 2016 (Value %)
Chapter 3 Global Asthma and COPD Market Analysis
3.1 Global Asthma and COPD Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Asthma and COPD Market
3.1 Global Asthma and COPD Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Asthma and COPD Market
Do Inquiry before Buying for this report at https://www.credenceresearch.com/inquiry-before-buying/58486
Chapter 4 Global Asthma and COPD Market Analysis, by Drug Type, 2015-2025 (US$ Mn)
4.1 Introduction
4.2 Anti-inflammatory drugs
4.2.1 Corticosteroids
4.2.2 Anti-Leukotrienes
4.2.3 Monoclonal antibodies
4.3 Bronchodilator monotherapy
4.3.1 Short-acting beta2-agonist (SABAs)
4.3.2 Long-acting beta2-agonist (LABAs)
4.3.3 Anticholinergics
4.4 Combination drugs
4.5 Pipeline Analysis
4.5.1 Projected sales of Phase III Asthma/COPD Drugs estimated till 2025 (US$ Mn)
4.5.1.1 GSK/INNOVIVA Fluticasone Furoate + Umeclidinium + Vilanterol (COPD)
4.5.1.2 Novartis Fevipiprant (Asthma)
4.5.1.3 Astrazeneca Tralokinumab (Asthma)
4.5.1.4 AstraZeneca/Kyowa Hakko Kirin Benralizumab (Asthma)
4.5.1.5 AstraZeneca Budesonide + formoterol (COPD)
4.5.1.6 AstraZeneca Budesonide + formoterol + glycopyrrolate (COPD)
4.5.1.7 AB Science Masitinib (Asthma)
4.5.1.8 GlaxoSmithKline Vilanterol (COPD)
4.5.1.9 Regeneron/Sanofi Dupilumab (Asthma)
4.5.1.10 Sunovion Sun-101(COPD)
4.5.1.11 Theravance Biopharma/Mylan Revefenacin (COPD)
4.5.1.12 Others
4.5.2 Tabular Representation of Phase II and I Drugs
4.1 Introduction
4.2 Anti-inflammatory drugs
4.2.1 Corticosteroids
4.2.2 Anti-Leukotrienes
4.2.3 Monoclonal antibodies
4.3 Bronchodilator monotherapy
4.3.1 Short-acting beta2-agonist (SABAs)
4.3.2 Long-acting beta2-agonist (LABAs)
4.3.3 Anticholinergics
4.4 Combination drugs
4.5 Pipeline Analysis
4.5.1 Projected sales of Phase III Asthma/COPD Drugs estimated till 2025 (US$ Mn)
4.5.1.1 GSK/INNOVIVA Fluticasone Furoate + Umeclidinium + Vilanterol (COPD)
4.5.1.2 Novartis Fevipiprant (Asthma)
4.5.1.3 Astrazeneca Tralokinumab (Asthma)
4.5.1.4 AstraZeneca/Kyowa Hakko Kirin Benralizumab (Asthma)
4.5.1.5 AstraZeneca Budesonide + formoterol (COPD)
4.5.1.6 AstraZeneca Budesonide + formoterol + glycopyrrolate (COPD)
4.5.1.7 AB Science Masitinib (Asthma)
4.5.1.8 GlaxoSmithKline Vilanterol (COPD)
4.5.1.9 Regeneron/Sanofi Dupilumab (Asthma)
4.5.1.10 Sunovion Sun-101(COPD)
4.5.1.11 Theravance Biopharma/Mylan Revefenacin (COPD)
4.5.1.12 Others
4.5.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Asthma and COPD Market, By Geography, 2015-2025 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, & Rest of APAC)
5.5 Latin America (Brazil, Mexico & Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, & Rest of APAC)
5.5 Latin America (Brazil, Mexico & Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)
Chapter 6 Company Profiles
6.1 Novartis AG
6.2 Merck & Co
6.3 Glaxosmithkline Plc
6.4 Boehringer Ingelheim Gmbh
6.5 Nycomed
6.6 Abbott Laboratories
6.7 AstraZeneca
6.8 Roche Holding AG
6.9 Teva Pharmaceutical Industries
6.10 Vectura Group
6.11 Pfizer Inc.
6.1 Novartis AG
6.2 Merck & Co
6.3 Glaxosmithkline Plc
6.4 Boehringer Ingelheim Gmbh
6.5 Nycomed
6.6 Abbott Laboratories
6.7 AstraZeneca
6.8 Roche Holding AG
6.9 Teva Pharmaceutical Industries
6.10 Vectura Group
6.11 Pfizer Inc.
No comments:
Post a Comment